BioTime to Present Additional Data at Upcoming ARVO

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Maryland, May 7-11. “This presentation is in addition to the poster presentation based on data

Full Story →